Products
Oritavancin was approved in the United States in 2014 as an infusion preparation (Orbactiv). The drug has not yet been registered in many countries.
Structure and properties
Oritavancin is present in drugs as oritavancin phosphate (C86H97N10O26Cl3 – 2H3PO4, Mr = 1989.1 g/mol) is present, a complex semisynthetically produced lipoglycopeptide structurally related to other glycopeptide antibiotics.
Effects
Oritavancin (ATC J01XA05) has bactericidal properties against Gram-positive pathogens. The effects are based on inhibition of bacterial cell wall formation. The drug has a very long half-life of 245 hours.
Indications
For the treatment of acute bacterial skin infections caused by Gram-positive pathogens such as staphylococci, streptococci, and enterococci.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion. Because of its long half-life, it can be injected as a single dose.
Contraindications
Oritavancin is contraindicated in the presence of hypersensitivity and in combination with intravenous heparin sodium. For complete precautions, see the drug label.
Interactions
Oritavancin is a weak inhibitor of CYP2C9 and CYP2C19 and a CYP inducer.
Adverse effects
The most common potential adverse effects include headache, nausea, vomiting, abscesses, and diarrhea.
